Gordon R Freeman

US Patent:

20100040614, Feb 18, 2010

Filed:

Dec 26, 2007

Appl. No.:

12/521302

Inventors:

Rafi Ahmed - Atlanta GA, US
Rama Amara - Atlanta GA, US
Gordon Freeman - Brookline MA, US
Arlene Sharpe - Brookline MA, US

International Classification:

A61K 39/395
A61K 39/00
A61P 31/12

US Classification:

4241331, 4241841, 4241731, 4241541

Abstract:

PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

US Patent:

20100151492, Jun 17, 2010

Filed:

Nov 27, 2009

Appl. No.:

12/626848

Inventors:

Rafi Ahmed - Atlanta GA, US
Rama Amara - Decatur GA, US
Vijayakumar Velu - Tucker GA, US
Gordon Freeman - Brookline MA, US

International Classification:

G01N 33/53
C12Q 1/02

US Classification:

435 72, 435 29

Abstract:

PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.

US Patent:

20120251537, Oct 4, 2012

Filed:

Mar 30, 2012

Appl. No.:

13/436492

Inventors:

Rafi Ahmed - Atlanta GA, US
Rama Amara - Atlanta GA, US
Gordon Freeman - Brookline MA, US
Arlene Sharpe - Brookline MA, US

International Classification:

A61K 39/12
A61K 39/21
A61K 39/245
A61K 39/25
A61K 39/29
A61K 39/235
A61K 39/23
A61P 31/14
A61P 31/22
A61P 31/20
A61P 31/18
A61P 37/04
A61P 35/00
A61K 39/00
A61P 31/00
A61K 39/395

US Classification:

4241341, 4242041, 4241731, 4241531, 4241331, 4242071, 4242301, 4242311, 4242251, 4242331, 4242081, 4242281, 4241841

Abstract:

PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

US Patent:

20170146520, May 25, 2017

Filed:

Feb 6, 2017

Appl. No.:

15/425856

Inventors:

- Atlanta GA, US
- Boston MA, US
Vijayakumar Velu - Tucker GA, US
Kehmia Titanji - Atlanta GA, US
Gordon Freeman - Brookline MA, US

Assignee:

Emory University - Atlanta GA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

G01N 33/50
A61K 39/00
A61K 39/12
C07K 16/28
C12N 15/113

Abstract:

PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.